ArticleLung cancer (Amsterdam, Netherlands)2014
Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer.
Article in Lung cancer (Amsterdam, Netherlands), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Do lung cancer patients require routine anticoagulation treatment? A meta-analysis.The Journal of international medical research · 2020Pooled it
- Cardiovascular comorbidities and their prognostic value in small cell lung cancer patients with chemoradiotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.Journal of thrombosis and thrombolysis · 2023Article
- A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients.Cancers · 2023Article
- Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.The oncologist · 2023Article
- Cancer Histology and Natural History of Patients with Lung Cancer and Venous Thromboembolism.Cancers · 2022Article
- Association between Platelet Count with 1-year Survival in Patients with Cancer Cachexia.Journal of Cancer · 2021Article
- Association of Venous Thromboembolism and Early Mortality in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer.Cancer management and research · 2021Article
- Risk Factors and Clinical Significance of D-Dimer in the Development of Postoperative Venous Thrombosis in Patients with Lung Tumor.Cancer management and research · 2020Article
- Prognostic values of platelet-associated indicators in advanced breast cancer.Translational cancer research · 2019Article
- Prognostic Values of Platelet-Associated Indicators in Resectable Lung Cancers.Technology in cancer research & treatment · 2019Article
- Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill.Thrombosis journal · 2019Review
- Characteristics and Impacts of Venous Thromboembolism in Patients with Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2018Article
- Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients.Medical oncology (Northwood, London, England) · 2018Article
- Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism.TH open : companion journal to thrombosis and haemostasis · 2018Article
- Long-term Survival Associated with Crizotinib in a Lung Cancer Patient with a Pulmonary Artery Embolism.Chinese medical journal · 2018Article
- Risk factors and prognosis value of venous thromboembolism in patients with advanced non-small cell lung cancer: a case-control study.Journal of thoracic disease · 2017Article
- IQCA-TAVV: To explore the effect of P-selectin, GPIIb/IIIa, IL-2, IL-6 and IL-8 on deep venous thrombosis.Oncotarget · 2017Article
- Enhanced procoagulant activity of platelets after chemotherapy in non-small cell lung cancer.Cancer biology & therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesVenous thromboembolic events (VTE) are a leading cause of death in cancer patients. We hypothesized that early VTE (EVTE, within 3 months of diagnosis) in patients with lung cancer (LC) are associated with worse overall survival (OS). MATERIALS AND
methodsWe identified 727 patients with LC between 1998 and 2011. Late VTE (LVTE) were defined as VTE occurring after 3 months from LC diagnosis. Advance disease (AD) was defined as patients with Stage IV non-small cell lung cancer (NSCLC) or extensive stage small cell lung cancer (SCLC), and non-advanced disease (non-AD) was defined as ≤ Stage III NSCLC or limited stage SCLC.
resultsOut of 727 patients included in our review, 617 patients had NSCLC (85%), 94 (13%) SCLC, and 16 (2%) low grade neuroendocrine tumors. Ninety five patients (13%) experienced VTE, 44 (6%) experienced an EVTE and 49 (7%) had a LVTE. Patients with an EVTE had worse OS when compared to all other patients (medians 4 vs. 17 months, p < 0.0001). EVTE were associated with worse OS in patients with non-AD (medians 12 vs. 42 months, p = 0.01) and AD (medians 4 vs. 6 months, p = 0.02). When considering patients with NSCLC only, in a multivariate model that included age, stage, performance status >2, administration of chemotherapy and Charlson comorbidity index, EVTE were an independent predictor of increased mortality (HR 2.4; 95% CI 1.6-3.3).
conclusionsEVTE are associated with worse OS, irrespective of stage of the disease. Our findings underscore the need for an efficient preventive strategy for VTE among patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.